A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
Clinical trial NCT04060862 · TERMINATED
Trial details
- NCT number
- NCT04060862
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-21
- Primary completion
- 2023-08-29
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.